<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5c5c5dae-4998-4752-8621-c5033e577298"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Calcium Acetate Capsules safely and effectively. See full prescribing information for Calcium Acetate Capsules.<br/>
      <br/>Calcium Acetate capsules, for oral use <br/>Initial U.S. Approval: 1990</title>
   <effectiveTime value="20250401"/>
   <setId root="a23b6070-eb4b-48e3-b563-8232206a6be4"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="118546603" root="1.3.6.1.4.1.519.1"/>
            <name>Cardinal Health 107, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ec090b6d-57cf-40fd-855a-7b6b62afbadc"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20200901"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55154-4169" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Calcium Acetate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Calcium Acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0904-7119" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="667"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y882YXF34X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2M83C4R6ZB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CALCIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PN2ZH5LOQY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 3</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="55154-4169-0" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20080226"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077728" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20080226"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>Blue Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">54215</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_eb8abf8d-d9c2-445e-a58f-7a19eb293e75">
               <id root="eceb3bfa-f5c1-4219-afe3-92abbe38bdd3"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Calcium acetate is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. (<linkHtml href="#i4i_indications_id_eb8abf8d-d9c2-445e-a58f-7a19eb293e75">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_2af48b8b-206f-4880-8ef0-24435a9f2778">
               <id root="4de70cbd-660d-4d85-bedc-75c6de10faad"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended initial dose of calcium acetate for the adult dialysis patient is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3 to 4 capsules with each meal.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Starting dose is 2 capsules with each meal. (<linkHtml href="#i4i_dosage_admin_id_2af48b8b-206f-4880-8ef0-24435a9f2778">2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Most patients require 3 to 4 capsules with each meal. (<linkHtml href="#i4i_dosage_admin_id_2af48b8b-206f-4880-8ef0-24435a9f2778">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_form_strength_id_b466df59-04dc-4ca6-9499-73da38022582">
               <id root="52def0b5-ecab-4f2e-9df0-fbb837d64c89"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Capsule: 667 mg calcium acetate capsule.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Capsule: 667 mg calcium acetate capsule. (<linkHtml href="#i4i_dosage_form_strength_id_b466df59-04dc-4ca6-9499-73da38022582">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_69f5f21f-fb61-4755-bbbc-014b94f1dec1">
               <id root="23269805-5780-4149-9207-1d21f90b2b61"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Patients with hypercalcemia.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypercalcemia. (<linkHtml href="#i4i_contraindications_id_69f5f21f-fb61-4755-bbbc-014b94f1dec1">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_precautions_id_f600284e-efe3-479a-8cb4-08136dba38d8">
               <id root="0567874b-71e9-42bf-80a2-99f0f3897500"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230302"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Treat mild hypercalcemia by reducing or interrupting calcium acetate and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate. (<linkHtml href="#i4i_section_id_74d9dce4-adc9-4bd6-b08a-ab5288a25042">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hypercalcemia may aggravate digitalis toxicity. (<linkHtml href="#i4i_section_id_7f990065-5597-4358-80a7-91c454c774b0">5.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_section_id_74d9dce4-adc9-4bd6-b08a-ab5288a25042">
                     <id root="4edc8a7c-bfaf-4a45-9460-0f2074dd6e44"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypercalcemia</title>
                     <text>
                        <paragraph>Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate. Avoid the use of calcium supplements, including calcium based nonprescription antacids, concurrently with calcium acetate. </paragraph>
                        <paragraph>An overdose of calcium acetate may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the calcium acetate dosage, or discontinue the treatment, depending on the severity of hypercalcemia.</paragraph>
                        <paragraph>More severe hypercalcemia (Ca &gt;12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy.</paragraph>
                        <paragraph>Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well.</paragraph>
                        <paragraph>Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long term effect of calcium acetate on the progression of vascular or soft tissue calcification has not been determined.</paragraph>
                        <paragraph>Hypercalcemia (&gt;11 mg/dL) was reported in 16% of patients in a 3 month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment. </paragraph>
                        <paragraph>Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg<sup>2</sup>/dL<sup>2</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_7f990065-5597-4358-80a7-91c454c774b0">
                     <id root="fa7bc6f5-ed08-4d32-89ce-5a29d97bc1f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Concomitant Use with Medications</title>
                     <text>
                        <paragraph>Hypercalcemia may aggravate digitalis toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_7872ae0e-14de-4395-b215-550465e97c1a">
               <id root="55f79c90-17c1-48ad-9e32-5e4bc28d2971"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Hypercalcemia is discussed elsewhere <content styleCode="italics">[see <linkHtml href="#i4i_section_id_74d9dce4-adc9-4bd6-b08a-ab5288a25042">Warnings and Precautions (5.1)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>The most common (&gt;10%) adverse reactions are hypercalcemia, nausea and vomiting. (<linkHtml href="#i4i_section_id_bfa25502-4388-4b63-a1c0-eb78b124d969">6.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy. (<linkHtml href="#i4i_adverse_effects_id_7872ae0e-14de-4395-b215-550465e97c1a">6</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_section_id_bfa25502-4388-4b63-a1c0-eb78b124d969">
                     <id root="84c96e55-b85d-41b7-8e96-53a418074237"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In clinical studies, calcium acetate has been generally well tolerated.</paragraph>
                        <paragraph>Calcium acetate was studied in a 3 month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and an alternate liquid formulation of calcium acetate was studied in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (&gt;2% on treatment) from these trials are presented in Table 1.</paragraph>
                        <table ID="_RefIDC8C5182449F1414095EB31EF92C70146" width="100%">
                           <caption>Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis </caption>
                           <col width="16%"/>
                           <col width="23%"/>
                           <col width="19%"/>
                           <col width="21%"/>
                           <col width="23%"/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Preferred Term</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Total adverse reactions reported for calcium acetate</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=167</content>
                                    </paragraph>
                                    <paragraph>N (%)</paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">3 month, open label study of calcium acetate</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=98</content>
                                    </paragraph>
                                    <paragraph>N (%)</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Double blind, placebo-controlled, cross-over study of liquid calcium acetate</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=69</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Calcium acetate</content>
                                    </paragraph>
                                    <paragraph>N (%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>N (%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6 (3.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6 (6.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4 (2.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4 (4.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Hypercalcemia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>21 (12.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>16 (16.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>5 (7.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0 (0.0)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting. More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate<content styleCode="bold">-</content>induced hypercalcemia. Isolated cases pruritus have been reported, which may represent allergic reactions.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_2483c19f-1e5e-4f41-a477-c65897841f72">
                     <id root="b7e390a5-83eb-4438-80c2-87a5fbfc688b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure. </paragraph>
                        <paragraph>The following additional adverse reactions have been identified during post-approval of calcium acetate: dizziness, edema, and weakness.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_interactions_id_5ee68562-6ffa-451a-ba47-d87697280e9c">
               <id root="356fc581-6455-43e4-998f-9cac84128f4f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl, and hydroxyl groups). Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism. </paragraph>
                  <paragraph>There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs. When administering an oral medication with calcium acetate where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Calcium acetate may decrease the bioavailability of tetracyclines or fluoroquinolones. (<linkHtml href="#i4i_interactions_id_5ee68562-6ffa-451a-ba47-d87697280e9c">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate or consider monitoring blood levels of the drug. (<linkHtml href="#i4i_interactions_id_5ee68562-6ffa-451a-ba47-d87697280e9c">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_section_id_e37f586c-72a0-4464-86f7-5154d64eaa52">
                     <id root="38c45b46-67c1-4b8c-8480-bfeed053543c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Ciprofloxacin</title>
                     <text>
                        <paragraph>In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets, approximately 2.7g, decreased the bioavailability of ciprofloxacin by approximately 50%.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_specific_populations_id_b6a5aece-f190-4dd2-ad89-95511610859b">
               <id root="2eb9c157-4431-4191-bf48-16d7f6fac866"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20230302"/>
               <component>
                  <section ID="i4i_pregnancy_id_c14c3a67-e37a-4790-83d8-412704748734">
                     <id root="4e617f63-a19e-44bc-a02a-bd0d8fc27829"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Pregnancy Category C:</content>
                        </paragraph>
                        <paragraph>Calcium acetate capsules contains calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#i4i_section_id_74d9dce4-adc9-4bd6-b08a-ab5288a25042">5.1</linkHtml>)]</content>. Maintenance of normal serum calcium levels is important for maternal and fetal well being. Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_labour_delivery_id_70388980-a37f-4a12-9d1c-b801b1daee5a">
                     <id root="38bef0ec-4041-4b8a-8d57-627aee676ba7"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Labor and Delivery</title>
                     <text>
                        <paragraph>The effects of calcium acetate on labor and delivery are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_3b638d7b-c699-4c75-9b40-e20e340c0bb6">
                     <id root="1bd6650e-95ee-40ad-96b9-d446c4f81ff0"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Calcium acetate capsules contains calcium acetate and is excreted in human milk. Human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_1d193629-c58e-4678-a0c5-e84a20f5ba49">
                     <id root="c694d60d-f4c1-4879-aa58-e27dd4d3e60c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_13264a5a-91f6-4a6a-aac1-a9e3de66a7ef">
                     <id root="e52b931f-2b56-4b01-a315-6f9a91333d8b"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_overdosage_id_56d2167f-9475-4a76-b39c-1c68d1414c40">
               <id root="aac2f520-e907-4d59-a842-43866bc90b4e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Administration of calcium acetate in excess of the appropriate daily dosage may result in hypercalcemia <content styleCode="italics">[see <linkHtml href="#i4i_section_id_74d9dce4-adc9-4bd6-b08a-ab5288a25042">Warnings and Precautions (5.1)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230302"/>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_18bbbfac-97bf-4148-b228-5131d54bc9f2">
               <id root="c7ee09a3-c6cc-4694-adeb-b4286a81a3e1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Calcium acetate acts as a phosphate binder. Its chemical name is calcium acetate. Its molecular formula is C<sub>4</sub>H<sub>6</sub>CaO<sub>4</sub>, and its molecular weight is 158.17. Its structural formula is:</paragraph>
                  <renderMultiMedia ID="id464" referencedObject="id_21eff547-59e0-4188-a237-2a6f6643f327"/>
                  <paragraph>Each white opaque/blue opaque capsule contains 667 mg of calcium acetate, USP (anhydrous; Ca(CH<sub>3</sub>COO)<sub>2</sub>; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, polyethylene glycol 8000 and magnesium stearate. Each capsule shell contains: black monogramming ink, FD&amp;C Blue #1, FD&amp;C Red #3, gelatin and titanium dioxide. The black monogramming ink contains: ammonium hydroxide, iron oxide black, isopropyl alcohol, n-butyl alcohol, propylene glycol and shellac glaze.</paragraph>
                  <paragraph>Calcium Acetate Capsules, USP are administered orally for the control of hyperphosphatemia in end-stage renal failure.</paragraph>
               </text>
               <effectiveTime value="20200901"/>
               <component>
                  <observationMedia ID="id_21eff547-59e0-4188-a237-2a6f6643f327">
                     <text>chem.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="1ddf6426-9aca-49cf-93f8-479feb2c4ded-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_dead0cfd-98b1-458b-a09a-9c6a5d5a874c">
               <id root="93086f19-1089-441d-8784-502e666f43fe"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD.</paragraph>
               </text>
               <effectiveTime value="20230302"/>
               <component>
                  <section ID="i4i_mechanism_action_id_3e942a18-9824-41fe-863b-949ef723347c">
                     <id root="7470b603-cfbd-467b-9c0c-cc070f3b8fcb"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pharmacodynamics_id_6d4d81c3-a2e5-4e85-91b8-95bae5b3af33">
                     <id root="f99fd23a-c5b5-4c1e-8391-ca345b736c70"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under nonfasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_nonclinical_toxicology_id_675bc1b5-80d5-4222-b0f4-287a3084bf07">
               <id root="b932db3d-a52f-4eb9-a917-62c6a103b173"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230302"/>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_661f5862-83d9-4aee-8eb6-d8ef202150ae">
                     <id root="229f12b5-17c3-420b-947e-fc226603261e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate.</paragraph>
                     </text>
                     <effectiveTime value="20230302"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_studies_id_6c411a0b-92cb-4f7a-a1d7-2453db822fd3">
               <id root="a939b585-97b7-4436-befb-257deef1a1ca"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid oral dosage form. </paragraph>
                  <paragraph>Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus &gt;5.5 mg/dL) following a 1 week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study. </paragraph>
                  <paragraph>The patients received calcium acetate 667 mg tablets at each meal for a period of 12 weeks. The initial starting dose was 2 tablets per meal for 3 meals a day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was a decrease in serum phosphorus, in the absence of a control group the true magnitude of effect is uncertain. </paragraph>
                  <paragraph>The data presented in Table 2 demonstrate the efficacy of calcium acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum calcium levels are also presented.</paragraph>
                  <table ID="_RefID0844B0DE6A21437C9825B098FC3F4D6B" width="100%">
                     <caption>Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study, Interim, and Study Completion Time Points </caption>
                     <col width="27%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <col width="12%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Parameter</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Pre-Study</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Week 4</content>
                                 <footnote ID="_Ref348597417">Ninety-one patients completed at least 6 weeks of the study.</footnote>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Week 8</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Week 12</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">p-value</content>
                                 <footnote ID="_Ref348597449">ANOVA of difference in values at pre-study and study completion.</footnote>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Phosphorus (mg/dL)<footnote ID="_Ref348597293">Values expressed as mean ± SE.</footnote>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>7.4 ± 0.17</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>5.9 ± 0.16</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>5.6 ± 0.17</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>5.2 ± 0.17</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>≤0.01</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>Calcium (mg/dL)<footnoteRef IDREF="_Ref348597293"/>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>8.9 ± 0.09</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>9.5 ± 0.10</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>9.7 ± 0.10</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>9.7 ± 0.10</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>≤0.01</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>There was a 30% decrease in serum phosphorus levels during the 12 week study period (p&lt;0.01). Two-thirds of the decline occurred in the first month of the study. Serum calcium increased 9% during the study mostly in the first month of the study. </paragraph>
                  <paragraph>Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into a double-blind, placebo-controlled, cross-over study. Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following 2 weeks of treatment, patients switched to the alternative therapy for an additional 2 weeks. </paragraph>
                  <paragraph>The phosphate binding effect of calcium acetate is shown in the Table 3.</paragraph>
                  <table ID="_RefID534F554BBA5745419B0A5F6DDDC616B3" width="100%">
                     <caption>Table 3: Serum Phosphorous and Calcium Levels at Study Initiation and After Completion of Each Treatment Arm </caption>
                     <col width="22%"/>
                     <col width="22%"/>
                     <col width="22%"/>
                     <col width="18%"/>
                     <col width="18%"/>
                     <tbody>
                        <tr>
                           <td rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Parameter</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Pre-Study</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Post-Treatment</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">p-value</content>
                                 <footnote ID="_Ref348597934">ANOVA of calcium acetate vs. placebo after 2 weeks of treatment.</footnote>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top"/>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Calcium Acetate</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="italics">Placebo</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top"/>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Phosphorus (mg/dL)<footnote ID="_RefID3FD32BE68CBD47C9A58567D303F4DB56">Values expressed as mean ± SEM.</footnote>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>7.3 ± 0.18</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>5.9 ± 0.24</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>7.8 ± 0.22</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>&lt;0.01</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>Calcium (mg/dL)<footnoteRef IDREF="_RefID3FD32BE68CBD47C9A58567D303F4DB56"/>  </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>8.9 ± 0.11</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>9.5 ± 0.13</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>8.8 ± 0.12</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>&lt;0.01</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Overall, 2 weeks of treatment with calcium acetate statistically significantly (p&lt;0.01) decreased serum phosphorus by a mean of 19% and increased serum calcium by a statistically significant (p&lt;0.01) but clinically unimportant mean of 7%.</paragraph>
               </text>
               <effectiveTime value="20200901"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_f240ac3c-d59b-4150-b879-64a5393fca68">
               <id root="b93530e9-7050-40f2-a08c-e0f7657d41f4"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Calcium Acetate Capsules, USP </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">667 mg capsule is supplied as a white opaque/blue opaque capsule, imprinted with “54 215” on the cap and body.</content>
                  </paragraph>
                  <paragraph>Overbagged with 10 capsules per bag, NDC 55154-4169-0</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</paragraph>
               </text>
               <effectiveTime value="20200901"/>
            </section>
         </component>
         <component>
            <section ID="i4i_info_patients_id_687b6605-e2aa-4eae-b902-8230ea46c9c3">
               <id root="92fc2e3b-e4aa-4a50-aeb3-3b9053a2c365"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Inform patients to take calcium acetate capsules with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia <content styleCode="italics">[see <linkHtml href="#i4i_section_id_74d9dce4-adc9-4bd6-b08a-ab5288a25042">Warnings and Precautions (5.1)</linkHtml>and <linkHtml href="#i4i_section_id_bfa25502-4388-4b63-a1c0-eb78b124d969">Adverse Reactions (6.1)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety or efficacy to take the drug one hour before or three hours after calcium acetate capsules.</paragraph>
                  <paragraph>Distr. by:<content styleCode="bold"> Hikma</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmaceuticals USA Inc.</content>
                  </paragraph>
                  <paragraph>Berkeley Heights, NJ 07922</paragraph>
                  <paragraph>
                     <content styleCode="bold">Packaged and Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MAJOR® PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>Indianapolis, IN 46268 USA</paragraph>
                  <paragraph>Refer to package label for Distributor's NDC Number</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed By:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardinal Health </content>
                  </paragraph>
                  <paragraph>Dublin, OH 43017</paragraph>
                  <paragraph>L57839070325</paragraph>
                  <paragraph>
                     <content styleCode="bold">C50000408/01</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Revised September 2020</content>
                  </paragraph>
               </text>
               <effectiveTime value="20200901"/>
            </section>
         </component>
         <component>
            <section ID="ID_214045bf-764b-437f-aea4-e909cf8f88bc">
               <id root="d204e9a6-1d95-4c1f-bd19-e976c35a1b61"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel </title>
               <text>
                  <paragraph>NDC 55154-4169-0</paragraph>
                  <paragraph>CALCIUM ACETATE</paragraph>
                  <paragraph>CAPSULES, USP 667 mg</paragraph>
                  <paragraph>10 CAPSULES</paragraph>
                  <renderMultiMedia ID="id-1694911051" referencedObject="ID_9ed5a53c-5fc7-4c78-99fb-af46dd6aaf69"/>
               </text>
               <effectiveTime value="20200901"/>
               <component>
                  <observationMedia ID="ID_9ed5a53c-5fc7-4c78-99fb-af46dd6aaf69">
                     <text>667mg bag label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="454bd52f-2207-47c9-95c0-d59fd38b87c7-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>